AdaptiM3D is a spin-out from the University of Strathclyde
It brings academic research excellence into practical application for the pharmaceutical industry.
One third of the 500,000 annual global early phase clinical trials are halted due to prediction errors of the required human dose. Re-formulation and manufacture of an adjusted dose tablet introduces up to 6 months delay with an estimated loss in sales of tens of millions of dollars per month.
AdaptiM3D has developed a novel, integrated table-top 3-D printing system that enables agile and rapid manufacture of clinical trial supplies. This transformative approach eliminates current multi-step manufacturing processes, shrinking space requirements from a factory to a room. This patent pending technology combined with the team’s formulation expertise can provide 2-3 months of time saving, worth tens of millions of dollars per trial.
AdaptiM3D’s technology is supported by an experienced team with decades of experience in formulation, manufacturing and quality systems, with access to a fully-licensed GMP pharmaceutical manufacturing facility at the University of Strathclyde.
We’re working to deliver the following clinical supply benefits.
Providing clinical trial supplies for trials within 1 month, enabling earlier product availability
Saving at least 2-3 months on the critical path for clinical trial supply by replacing multiple processes with one operation
Reducing manufacturing costs for clinical trial supply by 30-50% - by simplifying the manufacturing process
Addressing the issue that causes one-third of phase II clinical trials to be stopped for up to 6 months – on the critical path to product launch - due to suboptimal dose selection
Enabling rapid re-supply after a dose change, reducing total clinical trial elapsed times by eliminating 3-4 months of the 6-month delay for reformulation and manufacturing
Benefits to Small Biotechs
Our technology provides particular advantages to small biotech companies, who often face significant challenges with clinical trial delays and costs. AdaptiM3D's solution allows these companies to be more agile and cost-effective in their drug development process, reducing costs for clinical supply manufacturing.
The Team
The core team has over 90 years of experience in pharmaceutical formulation, process development, manufacturing and business development, and has the experience and capabilities to develop the company rapidly with a blend of technical, multinational and small company experience.
Technical expertise includes pharmaceutics (CMAC / Strathclyde), clinical trial manufacturing (Cancer Research UK) and engineering scale-up (GSK and CMAC); commercial experience spans technology licensing (GSK / SR One) and CDMO sales (Aptuit).
Business lead
Dr Mark Wilson
Business development professional with 20+ years of experience of deal and alliance management experience at GSK
Led technology divestment and spin-out activity at SR One (GSK’s venture fund)
Conducted expert advisory work for the UK Government, the European Commission (IP Directorate) and the World Intellectual Property Organisation (WIPO)
Commercial adviser
Massimo Bresciani
Commercial experience in contract sales at Aptuit (CDMO); responsible for industrial engagement at CMAC
Prior technical experience in product development at GSK
Science and technology lead
Prof John Robertson
Experience at GSK and CMAC; expertise in process intensification in pharmaceutical manufacturing
GSK: 20 years of industrial experience in development and deployment of strategic and disruptive pharmaceutical manufacturing technologies across an array of drug delivery approaches (oral, inhaled, transdermal, steriles).
Strathclyde / CMAC: 10 years of pre-competitive pharmaceutical technology development with 10 blue chip major international pharmaceutical companies
Author of >40 peer reviewed papers and patents
Manufacturing and product lead
Prof Gavin Halbert OBE
Former Director of the Cancer Research UK Formulation Unit at the University of Strathclyde
Pharmacist, Chemist and Qualified Person with 30 years experience of pharmaceutically progressing over 60 novel anticancer agents into clinical trial, including temozolomide and abiraterone acetate.
Career grant total of over £57 million and a combined total of over 200 publications, patents and presentations.
Scientific adviser
Prof Alistair Florence
Distinguished Professor in Pharmaceutical Sciences at the University of Strathclyde and Director of CMAC
Leads a number of major programmes across the portfolio including the EPSRC Future CMAC Manufacturing Research Hub, Made Smarter Innovation - Digital Medicines Manufacturing Research Centre (DM²) and CMAC National Facility.
Deep technical expertise in pharmaceutics and material properties
Leader of research projects and programmes that have been awarded grants in excess of £80M